Report Detail
Global (United States, European Union and China) Uterine Fibroid Embolization Agents Market Research Report 2019-2025
- RnM3623460 |
- 29 July, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. The embolization agents block the arteries supplying blood to the tumor and force them to shrink.
The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
In 2019, the market size of Uterine Fibroid Embolization Agents is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Uterine Fibroid Embolization Agents.
This report studies the global market size of Uterine Fibroid Embolization Agents, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Uterine Fibroid Embolization Agents sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Astellas Pharma
Nippon Kayaku
Pfizer
Boston Scientific Corporation
Merit Medical Systems
Cook Medical
...
Market Segment by Product Type
Gelatin Sponge
Polyvinyl Alcohol (PVA) Particles
Trisacryl Gelatin Microspheres (TAGM)
Polymethyl Methacrylate (PMMA) Microspheres
Others
Market Segment by Application
Clinical Research Institutes
Hospital
Surgical Centers
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Uterine Fibroid Embolization Agents status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Uterine Fibroid Embolization Agents manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Uterine Fibroid Embolization Agents are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Uterine Fibroid Embolization Agents Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Gelatin Sponge
- 1.3.3 Polyvinyl Alcohol (PVA) Particles
- 1.3.4 Trisacryl Gelatin Microspheres (TAGM)
- 1.3.5 Polymethyl Methacrylate (PMMA) Microspheres
- 1.3.6 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Uterine Fibroid Embolization Agents Market Share by Application (2019-2025)
- 1.4.2 Clinical Research Institutes
- 1.4.3 Hospital
- 1.4.4 Surgical Centers
- 1.4.5 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Uterine Fibroid Embolization Agents Market Size
- 2.1.1 Global Uterine Fibroid Embolization Agents Revenue 2014-2025
- 2.1.2 Global Uterine Fibroid Embolization Agents Sales 2014-2025
- 2.2 Uterine Fibroid Embolization Agents Growth Rate by Regions
- 2.2.1 Global Uterine Fibroid Embolization Agents Sales by Regions 2014-2019
- 2.2.2 Global Uterine Fibroid Embolization Agents Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Uterine Fibroid Embolization Agents Sales by Manufacturers
- 3.1.1 Uterine Fibroid Embolization Agents Sales by Manufacturers 2014-2019
- 3.1.2 Uterine Fibroid Embolization Agents Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Uterine Fibroid Embolization Agents Revenue by Manufacturers (2014-2019)
- 3.2.2 Uterine Fibroid Embolization Agents Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Uterine Fibroid Embolization Agents Market Concentration Ratio (CR5 and HHI)
- 3.3 Uterine Fibroid Embolization Agents Price by Manufacturers
- 3.4 Key Manufacturers Uterine Fibroid Embolization Agents Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Uterine Fibroid Embolization Agents Market
- 3.6 Key Manufacturers Uterine Fibroid Embolization Agents Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Gelatin Sponge Sales and Revenue (2014-2019)
- 4.1.2 Polyvinyl Alcohol (PVA) Particles Sales and Revenue (2014-2019)
- 4.1.3 Trisacryl Gelatin Microspheres (TAGM) Sales and Revenue (2014-2019)
- 4.1.4 Polymethyl Methacrylate (PMMA) Microspheres Sales and Revenue (2014-2019)
- 4.1.5 Others Sales and Revenue (2014-2019)
- 4.2 Global Uterine Fibroid Embolization Agents Sales Market Share by Type
- 4.3 Global Uterine Fibroid Embolization Agents Revenue Market Share by Type
- 4.4 Uterine Fibroid Embolization Agents Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Uterine Fibroid Embolization Agents Sales by Application
6 United States
- 6.1 United States Uterine Fibroid Embolization Agents Breakdown Data by Company
- 6.2 United States Uterine Fibroid Embolization Agents Breakdown Data by Type
- 6.3 United States Uterine Fibroid Embolization Agents Breakdown Data by Application
7 European Union
- 7.1 European Union Uterine Fibroid Embolization Agents Breakdown Data by Company
- 7.2 European Union Uterine Fibroid Embolization Agents Breakdown Data by Type
- 7.3 European Union Uterine Fibroid Embolization Agents Breakdown Data by Application
8 China
- 8.1 China Uterine Fibroid Embolization Agents Breakdown Data by Company
- 8.2 China Uterine Fibroid Embolization Agents Breakdown Data by Type
- 8.3 China Uterine Fibroid Embolization Agents Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Company
- 9.2 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Type
- 9.3 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Application
- 9.4 Rest of World Uterine Fibroid Embolization Agents Breakdown Data by Countries
- 9.4.1 Rest of World Uterine Fibroid Embolization Agents Sales by Countries
- 9.4.2 Rest of World Uterine Fibroid Embolization Agents Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Astellas Pharma
- 10.1.1 Astellas Pharma Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.1.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.1.5 Astellas Pharma Recent Development
- 10.2 Nippon Kayaku
- 10.2.1 Nippon Kayaku Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.2.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.2.5 Nippon Kayaku Recent Development
- 10.3 Pfizer
- 10.3.1 Pfizer Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.3.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.3.5 Pfizer Recent Development
- 10.4 Boston Scientific Corporation
- 10.4.1 Boston Scientific Corporation Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.4.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.4.5 Boston Scientific Corporation Recent Development
- 10.5 Merit Medical Systems
- 10.5.1 Merit Medical Systems Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.5.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.5.5 Merit Medical Systems Recent Development
- 10.6 Cook Medical
- 10.6.1 Cook Medical Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Uterine Fibroid Embolization Agents
- 10.6.4 Uterine Fibroid Embolization Agents Product Introduction
- 10.6.5 Cook Medical Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Uterine Fibroid Embolization Agents Sales Channels
- 11.2.2 Uterine Fibroid Embolization Agents Distributors
- 11.3 Uterine Fibroid Embolization Agents Customers
12 Market Forecast
- 12.1 Global Uterine Fibroid Embolization Agents Sales and Revenue Forecast 2019-2025
- 12.2 Global Uterine Fibroid Embolization Agents Sales Forecast by Type
- 12.3 Global Uterine Fibroid Embolization Agents Sales Forecast by Application
- 12.4 Uterine Fibroid Embolization Agents Forecast by Regions
- 12.4.1 Global Uterine Fibroid Embolization Agents Sales Forecast by Regions 2019-2025
- 12.4.2 Global Uterine Fibroid Embolization Agents Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Uterine Fibroid Embolization Agents. Industry analysis & Market Report on Uterine Fibroid Embolization Agents is a syndicated market report, published as Global (United States, European Union and China) Uterine Fibroid Embolization Agents Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Uterine Fibroid Embolization Agents market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
